Skip to content

A human study to evaluate of efficacy and safety of Euglena gracilis powder on immune function

A human study to evaluate of efficacy and safety of Euglena gracilis powder on immune function

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0004406
Enrollment
100
Registered
2019-10-31
Start date
2019-12-18
Completion date
Unknown
Last updated
2022-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Subjects take placebo or Euglena gracilis powder twice a day for 8 weeks

Sponsors

Daesang
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Subject who voluntarily agrees to participate and signs in informed consent form 2) Healthy people, 20 = age < 70. 3) Stress self assessment scaled above "strong" 4) Subjects suffered from upper respiratory track infection or cold-related symptoms which have possibilities to cause upper respiratory track infection more than two times in the past one year. 5) white blood cell(WBC) ranged from 4X10000 to 10X1000cells/ul.

Exclusion criteria

Exclusion criteria: 1) Patients who was diagnosed and are currently in the treatment of diabetes 2) Subjects who are currently in the treatment of significant clinical disease related to acute or chronic cardiovascular system, immune system, respiratory system, liver biliary, kidney and urinary tract, nervous system, musculoskeletal disorders, psychic, infection and blood neoplastic. 3) Subjects who have medical history with myocardial infarction or cerebrovascular diseasey within 6 months. 4) Subjects who have a neurologically or psychologically important medial history or who is currently suffering from a disease. 5) Subjects who have uncontrolled high blood pressure. 6) Subjects whose AST or ALT exceeds 3 times of normal range. 7) Subjects whose creatinine exceeds exceeds 2 times of normal range. 8) Subjects who have complained of severe gastrointestinal symptoms such as heartburn, indigestion. 9) Subjects who got a vaccination within 3months before screening. 10) Subjects whose BMI is under 18.5 or exceeds 30.0 11) Subjects who continue to consume beta-glucan or algae-containing food within one month of their first visit 12) Subjects who have intaken or is intaking functional foods 13) Subjects who are planning to participate other studies within one month of their first visit 14) Subjects who are pregnant or breastfeeding or planning a pregnancy. 15) Subjects who are sensitive to test foods/algae or have food allergies. 16) Subjects who are deemed to be inappropriate to this study.

Design outcomes

Primary

MeasureTime frame
NK cell activity (%) et al.

Secondary

MeasureTime frame
Adverse events et al.

Countries

Korea, Republic of

Contacts

Public ContactDoori Choi

Bundang Jesaeng Hospital

xhsldks07@naver.com+82-31-779-5077

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026